Recifercept

Recifercept (TA-46) is a recombinant human soluble fibroblast growth factor receptor 3, a decoy protein that competes for the ligand of mutant FGFR3.Recifercept is used in the study of chondrodysplasia because it restores normal bone growth by preventing negative inhibitory signaling of mutant FGFR3 in patients with pediatric chondrodysplasia.Recifercept is a recombinant human recombinant fibroblast growth factor receptor 3 that competes for the ligand of mutant FGFR3.

Methods: BaF3 cells overexpressing wild-type FGFR3 or the G380R mutant were established. Proliferation was induced with FGF1 (100 ng/mL), followed by treatment with Recifercept (0.1, 1, 10, 100, 1000 nM). Cell proliferation was assessed using the CellTiter-Glo assay.
Results: Recifercept dose-dependently inhibited FGF1-driven cell proliferation, with an IC₅₀ of 4.3 nM for wild-type FGFR3 and 3.6 nM for the G380R mutant. [1]

Methods: To investigate the therapeutic effects of Recifercept on mice with achondroplasia, a model of achondroplasia was established. Starting at 3 days of age, Recifercept (3 or 10 mg/kg) was administered via subcutaneous injection twice weekly for a total of 21 days. Body weight, body length, and long bone growth were assessed.
Results: Recifercept improved body weight and body length in a dose-dependent manner; a dose of 3 mg/kg was sufficient to fully restore the length of the humerus, ulna, femur, and tibia, while 10 mg/kg yielded even better results, with no significant adverse reactions. [1]

Human

Monoclonal

Unconjugated